Feature | May 17, 2013

Robotic Angioplasty Achieves 97.6 Percent Clinical Success Rate

Publication of PRECISE Trial Results builds on momentum of FDA clearance and commercialization of the CorPath System.

May 17, 2013 — The Journal of American College of Cardiology has published the results from Corindus Vascular Robotics’ CorPath PRECISE (Percutaneous Robotic-Enhanced Coronary Intervention) study in the April 2013 issue. Results of the trial demonstrate the vascular robotics CorPath System is safe and feasible for patients, with significantly lower harmful radiation exposure to the operator.

The study was a prospective, single-arm, multicenter, open-label, non-randomized study, enrolling 164 patients at nine clinical trial sites.

The primary endpoint of clinical procedural success was achieved in 97.6 percent of patients, and device technical success was achieved in 98.8 percent. Additionally, a secondary endpoint of the trial was the reduction in radiation exposure to the physician. Researchers determined the CorPath System significantly lowered radiation exposure by 95.2 percent compared to levels found when a physician performs the procedure at the patient’s bedside. Although operator comfort was not measured in the study, researchers noted the ability to perform procedures in a seated position without a heavy lead apron provides relief for back discomfort and allows the operator to focus solely on the patient.

Traditionally, angioplasty procedures are performed manually, where an interventional cardiologist inserts a guidewire with a stent or balloon attached to physically open an artery blockage and help improve blood flow. While angioplasty procedures remain one of the most frequently performed procedures in the United States with nearly one million cases annually, the procedure has remained largely unchanged for decades. A CorPath robotic angioplasty allows interventional cardiologists to perform the procedure remotely, away from the patient bedside. Seated in a radiation-protected cockpit, the physician uses a joystick to robotically advance catheters, angioplasty balloons and stents to clear the blockage and restore blood flow. Additionally, the technology provides interventional cardiologists with the ability to accurately measure anatomy and precisely control stents.

“At Sanford Health, we implemented two CorPath Systems in December, and we have already performed 34 procedures. Using a joystick, I am able to advance the catheter millimeter-by-millimeter through the artery and achieve enhanced control when placing the stent,” said Tom Stys, M.D., FACC, FSCAI, medical director at Sanford Heart Hospital and Cardiovascular Services, Sioux Falls, South Dakota. “With an increasing amount of complex procedures being performed, we feel it is essential to invest in new technology that will help physicians provide enhanced patient care.”

For more information: www.corindus.com

Related Content

coherex Wave Crest LAA Occluder

Coherex WaveCrest Left Atrial Appendage (LAA) Occlusion System.

News | November 24, 2015
November 24, 2015 — Biosense Webster announced it has acquired Coherex Medical Inc., a privately held medical device
Feature | Cath Lab| November 24, 2015
November 24, 2015 — The U.S.
Boston Scientific, Watchman FLX, LAA closure device, CE mark, first European implants

Image courtesy of Boston Scientific

News | Left Atrial Appendage (LAA) Occluders| November 20, 2015
Boston Scientific announced the first implants of the Watchman FLX left atrial appendage closure (LAAC) device
News | Cath Lab| November 10, 2015
TherOx Inc. announced it has received U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE)...
Sponsored Content | Videos | TCT| November 05, 2015
DAIC Editor Dave Fornell offers his choices for the most innovative new interventional cardiovascular technologies pr
Sponsored Content | Videos | TCT| November 05, 2015
Tom Watson, clinical analyst for MDBuyLine, and DAIC Dave Fornell discuss some of the technology trends at the 2015 T
CSI, OPTIMIZE study, peripheral orbital atherectomy system, peripheral artery disease, PAD

Diamondback 360 orbital atherectomy system. Image courtesy of Cardiovascular Systems Inc.

News | Atherectomy Devices| November 03, 2015
Cardiovascular Systems Inc. (CSI) announced last week that the first two patients have been enrolled in its OPTIMIZE,...
Sponsored Content | Videos | Cath Lab| November 03, 2015
Guillaume Baillaird, CEO of ControlRad Systems, described how his company's technology can significantly reduce radia
Overlay Init